GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » Intrinsic Value: Projected FCF

HeartBeam (HeartBeam) Intrinsic Value: Projected FCF : $0.00 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is HeartBeam Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-05), HeartBeam's Intrinsic Value: Projected FCF is $0.00. The stock price of HeartBeam is $2.21. Therefore, HeartBeam's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for HeartBeam's Intrinsic Value: Projected FCF or its related term are showing as below:

BEAT's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.275
* Ranked among companies with meaningful Price-to-Projected-FCF only.

HeartBeam Intrinsic Value: Projected FCF Historical Data

The historical data trend for HeartBeam's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartBeam Intrinsic Value: Projected FCF Chart

HeartBeam Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

HeartBeam Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HeartBeam's Intrinsic Value: Projected FCF

For the Health Information Services subindustry, HeartBeam's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartBeam's Price-to-Projected-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, HeartBeam's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where HeartBeam's Price-to-Projected-FCF falls into.



HeartBeam Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



HeartBeam  (NAS:BEAT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

HeartBeam's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.21/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartBeam Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of HeartBeam's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartBeam (HeartBeam) Business Description

Traded in Other Exchanges
N/A
Address
2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Its initial focus is providing diagnostic data to help physicians with the care management of patients with cardiovascular disease.
Executives
Urioste George De director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen officer: Chief Technology Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno officer: President 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein officer: Chief Financial Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel officer: Chief Operating Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard M Ferrari director, officer: Exec Chm of the BOD 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic 10 percent owner, officer: Chief Executive Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink director 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt officer: Chief Business Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050